Related Experiment Videos

Countering neurodegeneration by reducing the activity of the insulin/IGF signaling pathway: current knowledge and

Ehud Cohen1

  • 1Institute of Medical Research Israel-Canada, The Hebrew University of Jerusalem, Hadassah Medical School, Jerusalem, Israel. ehudc@ekmd.huji.ac.il

Experimental Gerontology
|September 21, 2010
PubMed

Insights

Reducing insulin/IGF signaling (IIS), a key aging pathway, protects against neurodegenerative diseases by preventing toxic protein buildup. This approach shows therapeutic potential for age-related brain disorders.

Area of Science:

  • Neuroscience
  • Aging Research
  • Molecular Biology

Background:

  • Neurodegenerative diseases are characterized by protein aggregation and late onset, suggesting a role for aging.
  • The Insulin/IGF signaling (IIS) pathway is a major regulator of aging and has been implicated in neuroprotection.

Purpose of the Study:

  • To review the protective mechanisms against neurodegeneration mediated by IIS.
  • To discuss the therapeutic potential of IIS reduction for neurodegenerative disorders.

Main Methods:

  • Review of existing literature on IIS, aging, and neurodegeneration.
  • Analysis of studies in model organisms (invertebrates and mice) investigating IIS manipulation and its effects on protein aggregation and disease phenotypes.

Main Results:

  • Reduced IIS protects model organisms from toxic protein aggregation linked to neurodegeneration.
  • This protective effect of reduced IIS is evolutionarily conserved, as demonstrated in Alzheimer's disease models.

Conclusions:

  • The aging process actively contributes to the late onset of neurodegenerative diseases.
  • IIS reduction presents a promising therapeutic strategy for treating neurodegenerative disorders by counteracting proteotoxicity.

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...